Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of tissue factor pathway inhibitor 2 attenuates trophoblast proliferation and invasion in preeclampsia

  • Research Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Pre-eclampsia (PE) is a disorder of pregnancy characterized by proteinuria and high blood pressure, affecting 2–8% of pregnancies worldwide. Previous studies have shown that PE is closely associated with trophoblast cell dysfunction. Here, we investigated the role of tissue factor pathway inhibitor-2 (TFPI-2) in regulating the biological processes of trophoblast cells. The TFPI-2 levels in plasma samples and placental tissues were tested by ELISA, immunohistochemistry, qRT-PCR, and western blot. HTR8/Svneo cell line was used to simulate the primary trophoblast cells and H/R culture was applied to mimic the oxidative stress state of PE. MTT assay, Annexin V/propidium iodide (PI) apoptosis assay, and transwell assay were used to determine the cell proliferation, apoptosis, and invasion. The expression levels of matrix metalloproteinases (MMPs) were evaluated by western blot. The expression of TFPI-2 was remarkably up-regulated in both the serum and placenta of PE patients. Hypoxia/reoxygenation increased the expression of TFPI-2 in HTR‐8/SVneo cell line. TFPI-2 promoted that cell proliferation and inhibited the cell apoptosis of HTR8/SVneo cells in H/R condition. In addition, downregulation of TFPI-2 increased the cell invasion and the expression of MMP2 and MMP9. This study reveals that TFPI-2 plays a crucial role in monitoring the biological function of trophoblast cells, which might provide theoretical basis and therapeutic targets for the treatment of PE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jim B, Karumanchi SA. Preeclampsia: pathogenesis, prevention, and long-term complications. Semin Nephrol. 2017;37(4):386–97. https://doi.org/10.1016/j.semnephrol.2017.05.011.

    Article  CAS  PubMed  Google Scholar 

  2. Leslie MS, Briggs LA. Preeclampsia and the risk of future vascular disease and mortality: a review. J Midwifery Womens Health. 2016;61(3):315–24. https://doi.org/10.1111/jmwh.12469.

    Article  PubMed  Google Scholar 

  3. Balci S, Bodur T, Tohma YA, Okyay RE, Saatli B, Altunyurt S. Do preeclampsia symptoms resolve after intrauterine death of a fetus? Turk J Obstet Gynecol. 2016;13(2):103–5. https://doi.org/10.4274/tjod.84770.

    Article  PubMed  PubMed Central  Google Scholar 

  4. van Esch JJA, van Heijst AF, de Haan AFJ, van der Heijden OWH. Early-onset preeclampsia is associated with perinatal mortality and severe neonatal morbidity. J Matern Fetal Neonatal Med. 2017;30(23):2789–94. https://doi.org/10.1080/14767058.2016.1263295.

    Article  CAS  PubMed  Google Scholar 

  5. Kongwattanakul K, Saksiriwuttho P, Chaiyarach S, Thepsuthammarat K. Incidence, characteristics, maternal complications, and perinatal outcomes associated with preeclampsia with severe features and HELLP syndrome. Int J Womens Health. 2018;10:371–7. https://doi.org/10.2147/IJWH.S168569.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lin S, Leonard D, Co MA, Mukhopadhyay D, Giri B, Perger L, et al. Pre-eclampsia has an adverse impact on maternal and fetal health. Transl Res. 2015;165(4):449–63. https://doi.org/10.1016/j.trsl.2014.10.006.

    Article  PubMed  Google Scholar 

  7. Ibanoglu MC, Ozgu-Erdinc AS, Uygur D. Maternal placi protein levels in early- and late-onset preeclampsia. Ginekol Pol. 2018;89(3):147–52. https://doi.org/10.5603/GP.a2018.0025.

    Article  PubMed  Google Scholar 

  8. Kornacki J, Skrzypczak J. Results of Doppler examinations in fetuses of mothers with early- and late-onset preeclampsia. Ginekol Pol. 2014;85(7):504–8.

    PubMed  Google Scholar 

  9. Palomaki GE, Martin JN Jr, Karumanchi SA, Poon LC. Updates on screening, prevention, treatment, and genetic markers for preeclampsia. Clin Chem. 2018;64(12):1684–9. https://doi.org/10.1373/clinchem.2018.289801.

    Article  CAS  PubMed  Google Scholar 

  10. Myatt L, Redman CW, Staff AC, Hansson S, Wilson ML, Laivuori H, et al. Strategy for standardization of preeclampsia research study design. Hypertension. 2014;63(6):1293–301. https://doi.org/10.1161/HYPERTENSIONAHA.113.02664.

    Article  CAS  PubMed  Google Scholar 

  11. Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol. 2016;11(6):1102–13. https://doi.org/10.2215/CJN.12081115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Song X, Luo X, Gao Q, Wang Y, Gao Q, Long W. Dysregulation of LncRNAs in placenta and pathogenesis of preeclampsia. Curr Drug Targets. 2017;18(10):1165–70. https://doi.org/10.2174/1389450118666170404160000.

    Article  CAS  PubMed  Google Scholar 

  13. Schneider H. Placental dysfunction as a key element in the pathogenesis of preeclampsia. Dev Period Med. 2017;21(4):309–16.

    PubMed  Google Scholar 

  14. Ali MN, Kasetty G, Elven M, Alyafei S, Jovic S, Egesten A, et al. TFPI-2 Protects against gram-negative bacterial infection. Front Immunol. 2018;9:2072. https://doi.org/10.3389/fimmu.2018.02072.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wang G, Huang W, Li W, Chen S, Chen W, Zhou Y, et al. TFPI-2 suppresses breast cancer cell proliferation and invasion through regulation of ERK signaling and interaction with actinin-4 and myosin-9. Sci Rep. 2018;8(1):14402. https://doi.org/10.1038/s41598-018-32698-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Xu C, Wang H, He H, Zheng F, Chen Y, Zhang J, et al. Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer. BMC Cancer. 2013;13:118. https://doi.org/10.1186/1471-2407-13-118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Weber M, Knoefler I, Schleussner E, Markert UR, Fitzgerald JS. HTR8/SVneo cells display trophoblast progenitor cell-like characteristics indicative of self-renewal, repopulation activity, and expression of "stemness-" associated transcription factors. Biomed Res Int. 2013;2013:243649. https://doi.org/10.1155/2013/243649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Cohen M, Bischof P. Factors regulating trophoblast invasion. Gynecol Obstet Invest. 2007;64(3):126–30. https://doi.org/10.1159/000101734.

    Article  PubMed  Google Scholar 

  19. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391–403. https://doi.org/10.1016/j.bpobgyn.2011.01.006.

    Article  PubMed  Google Scholar 

  20. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631–44. https://doi.org/10.1016/S0140-6736(10)60279-6.

    Article  PubMed  Google Scholar 

  21. von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr Hypertens Rep. 2014;16(8):454. https://doi.org/10.1007/s11906-014-0454-8.

    Article  CAS  Google Scholar 

  22. Feng C, Ho Y, Sun C, Xia G, Ding Q, Gu B. TFPI-2 expression is decreased in bladder cancer and is related to apoptosis. J BUON. 2016;21(6):1518–23.

    PubMed  Google Scholar 

  23. Zhao B, Luo X, Shi H, Ma D. Tissue factor pathway inhibitor-2 is downregulated by ox-LDL and inhibits ox-LDL induced vascular smooth muscle cells proliferation and migration. Thromb Res. 2011;128(2):179–85. https://doi.org/10.1016/j.thromres.2011.02.025.

    Article  CAS  PubMed  Google Scholar 

  24. Jia Y, Yang Y, Brock MV, Cao B, Zhan Q, Li Y, et al. Methylation of TFPI-2 is an early event of esophageal carcinogenesis. Epigenomics. 2012;4(2):135–46. https://doi.org/10.2217/epi.12.11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Karaszi K, Szabo S, Juhasz K, Kiraly P, Kocsis-Deak B, Hargitai B, et al. Increased placental expression of placental protein 5 (PP5)/tissue factor pathway inhibitor-2 (TFPI-2) in women with preeclampsia and HELLP syndrome: relevance to impaired trophoblast invasion? Placenta. 2019;76:30–9. https://doi.org/10.1016/j.placenta.2019.01.011.

    Article  CAS  PubMed  Google Scholar 

  26. Staun-Ram E, Shalev E. Human trophoblast function during the implantation process. Reprod Biol Endocrinol. 2005;3:56. https://doi.org/10.1186/1477-7827-3-56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Guleria I, Pollard JW. The trophoblast is a component of the innate immune system during pregnancy. Nat Med. 2000;6(5):589–93. https://doi.org/10.1038/75074.

    Article  CAS  PubMed  Google Scholar 

  28. Abbas Y, Oefner CM, Polacheck WJ, Gardner L, Farrell L, Sharkey A, et al. A microfluidics assay to study invasion of human placental trophoblast cells. J R Soc Interface. 2017. https://doi.org/10.1098/rsif.2017.0131.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Bertero MT, Camaschella C, Serra A, Bergui L, Caligaris-Cappio F. Circulating 'trophoblast' cells in pregnancy have maternal genetic markers. Prenat Diagn. 1988;8(8):585–90.

    Article  CAS  PubMed  Google Scholar 

  30. Wagner D, Schunck R, Isebarth H. Detection of trophoblast cells in the circulating blood of women with normal and complicated pregnancy. Gynaecologia. 1964;158:175–92.

    CAS  PubMed  Google Scholar 

  31. Chen H, Zhou X, Han TL, Baker PN, Qi H, Zhang H. Decreased IL-33 production contributes to trophoblast cell dysfunction in pregnancies with preeclampsia. Mediat Inflamm. 2018;2018:9787239. https://doi.org/10.1155/2018/9787239.

    Article  CAS  Google Scholar 

  32. Konduri SD, Tasiou A, Chandrasekar N, Rao JS. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol. 2001;18(1):127–31.

    CAS  PubMed  Google Scholar 

  33. Udagawa K, Miyagi Y, Hirahara F, Miyagi E, Nagashima Y, Minaguchi H, et al. Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Placenta. 1998;19(2–3):217–23.

    Article  CAS  PubMed  Google Scholar 

  34. Iochmann S, Blechet C, Chabot V, Saulnier A, Amini A, Gaud G, et al. Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion. Clin Exp Metastasis. 2009;26(5):457–67. https://doi.org/10.1007/s10585-009-9245-z.

    Article  CAS  PubMed  Google Scholar 

  35. Zhai LL, Wu Y, Huang DW, Tang ZG. Increased matrix metalloproteinase-2 expression and reduced tissue factor pathway inhibitor-2 expression correlate with angiogenesis and early postoperative recurrence of pancreatic carcinoma. Am J Transl Res. 2015;7(11):2412–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Zhai LL, Wu Y, Cai CY, Tang ZG. Upregulated matrix metalloproteinase-2 and downregulated tissue factor pathway inhibitor-2 are risk factors for lymph node metastasis and perineural invasion in pancreatic carcinoma. Onco Targets Ther. 2015;8:2827–34. https://doi.org/10.2147/OTT.S90599.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zhu B, Zhang P, Zeng P, Huang Z, Dong TF, Gui YK, et al. Tissue factor pathway inhibitor-2 silencing promotes hepatocellular carcinoma cell invasion in vitro. Anat Rec (Hoboken). 2013;296(11):1708–16. https://doi.org/10.1002/ar.22789.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The study was supported by the Hebei Science and Technology Support Project (17277739D).

Author information

Authors and Affiliations

  1. Department of Obstetrics, The Second Hospital of Hebei Medical University, No. 215 Heping Xi Road, Shijiazhuang, 050000, Hebei, China

    Lili Zheng, Jing Huang, Yuan Su, Fang Wang, Hongfang Kong & Hong Xin

Authors
  1. Lili Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuan Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongfang Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hong Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong Xin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

The experiments were approved by the Ethical Committee of the Second Hospital of Hebei Medical University.

Informed consent

All participants in this study were informed and gave written consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 404 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zheng, L., Huang, J., Su, Y. et al. Overexpression of tissue factor pathway inhibitor 2 attenuates trophoblast proliferation and invasion in preeclampsia. Human Cell 33, 512–520 (2020). https://doi.org/10.1007/s13577-020-00322-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-020-00322-0

Keywords

Search

Navigation